ments that are at least associated with better outcomes. 3, 6, 13, 15 This kind of statistical analysis may guide management and provide direction for new clinical trials.
In the present study, we used statistical methods to determine whether outcome after aneurysmal SAH depended on the country of treatment because it is widely believed, although not well documented, that treatment is "better" in some countries than in others. The relatively unique data obtained in 3567 patients entered into the randomized trials of tirilazad were used for this purpose.
Methods

Patient Population and Clinical Variables
Data obtained in 3567 patients with aneurysmal SAH entered into 4 randomized, double-blind, placebo-controlled clinical trials of tirilazad were analyzed. Patients were entered into the trials between 1991 and 1997 at 162 centers from 21 countries in Europe, Australia, North America, and Africa. 11, 14, 17, 18 Included countries were Aus tralia, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Italy, Mexico, Netherlands, Norway, New Zealand, Portugal, Russia, South Africa, Sweden, Switzerland, the UK, and the US. Inclusion criteria were patient age ≥ 18 years, SAH confirmed on CT scan or lumbar puncture, and angiographically confirmed saccular aneurysm as the cause of hemorrhage. Study drug or placebo treatment was started within 48 hours of SAH. Exclusion criteria were traumatic SAH, fusiform or mycotic aneurysm, severe concomitant medical, neurological, or psychiatric illnesses, serious cardiovascular illness such as an MI within the past 6 months, uncontrolled hypertension, or any Q-wave MI, serious cardiac arrhythmia, or congestive heart failure. Pregnant or lactating mothers were not eligible, and patients taking corticosteroids or calcium antagonists other than nimodipine prior to randomization or with a known intolerance to calcium antagonists were excluded. Almost all patients received nimodipine. The timing of surgery was decided by local investigators. No patient received Guglielmi or other detachable coils.
Admission data included age, sex, race, admission Glasgow Coma Scale score, 27 World Federation of Neurosurgical Societies grade, 8 admission systolic and diastolic blood pressures, time from ictus to admission and from admission to surgery, weight, and body temperature. Medical history including hypertension, MI, diabetes, liver disease, thyroid disease, migraine headaches, and previous SAH were recorded. Body temperature was documented again 8 days after SAH.
Recorded developments after hospitalization included symptomatic vasospasm, cerebral infarction, hydrocephalus, and pulmonary edema. Symptomatic vasospasm was defined as a ≥ 2-point decrease in Glasgow Coma Scale score or a 2-point increase in motor score on the National Institutes of Health Stroke Scale 5 lasting at least 8 hours. Other causes of deterioration had to be excluded by the investigators. Confirmation of vasospasm with transcranial Doppler ultrasonography or cerebral angiography was recommended but not mandatory. Complications were determined at each center and there was no central review. However, central review of some cases showed good agreement between diagnoses made at the sites and (14) 186 (12) 35 (11) 0 (0) severe disability 199 (12) 190 (13) 34 (11) 1 (20) vegetative state 29 (2) 24 (2) 6 (2) 0 (0) death 248 (15) 268 (18) 62 (20) 1 (20) * Ages are given as means ± SDs. Abbreviation: WFNS = World Federation of Neurological Societies.
at central review (N. Kassell, personal communication, January 31, 2006) . Recorded therapeutic interventions included aneurysm clipping (time from SAH to admission and time to clipping were recorded), anticonvulsant use, cerebral angioplasty, and whether prophylactic or therapeutic hemodilution, hypervolemia, or induced hypertension were used. Outcome was assessed 3 months after SAH with the 5-point GOS.
12 An unfavorable outcome was defined as death, vegetative state, or severe disability.
Radiological Variables
All radiological data were based on investigator interpretation. Subarachnoid hemorrhage on the admission CT scan was graded as absent, diffuse or localized thin, or diffuse or localized thick, with no quantitative definitions. Intracerebral hemorrhage, intraventricular hemorrhage, and hydrocephalus were recorded as present or absent on admission CT scans. Intrathecal fibrinolytic therapy was not allowed. The location of the ruptured aneurysm was recorded. In patients with multiple aneurysms, the pattern of blood on the CT scan was used to determine which aneurysm had ruptured. The maximum angiographically demonstrated diameter of the ruptured aneurysm was recorded as ≤ 12, 13-24, or ≥ 25 mm. Vasospasm on the initial angiogram was noted and recorded as acute vasospasm.
Statistical Analysis
Therapeutic Intervention Variabiliy by Geographic Location. We first investigated whether there was significant geographic variability in the therapeutic interventions used. This analysis was done 2 ways and was necessary because treatment variations must be present between countries, continents, and regions in this database. If treatment did not vary between countries, variation in outcomes due to differences in treatment could not occur. First, the relationship between each treatment and the other clinical, radiological, and treatment factors, as well as country, continent, or region, was determined by univariate analysis. Country was analyzed by the 21 countries, as well as by collapsing country into continent (North America, Europe, Oceania, and Other) or region (North America, Europe, Scandinavia, Oceania, and Other). All analyses were done with the data obtained in all patients, including 2695 with complete data and 1378 who received a placebo. Univariate analysis was performed with the chi-square test for categorical variables and 2 sample t-tests or Wilcoxon rank-sum tests for continuous variables. Next, variables significantly associated with a treatment (p < 0.05) were entered into multinomial logistic regression, with geography as the dependent variable, to adjust for variables identified in univariate analysis to be significantly associated with treatment. The outcome of this analysis determined whether treatment varied between country, continent, or region after accounting for other factors. Second, multivariate logistic regression was done using the treatment as the dependent variable. Independent variables were clinical, radiological, and other treatment variables, and country, continent, or region that were significant in the univariate analysis. The probability value for removal in this logistic regression was set at 0.15. Adjusted ORs with 95% CIs were calculated, and independence of variables was tested using the likelihood ratio test on reduced models.
Outcome Variability by Geographic Location. The second question was whether outcome varied between countries, continents, and regions. The GOS score 3 months after SAH was the dependent variable and was analyzed as a dichotomous or a 5-point variable. This was recorded in 3498 (98%) of 3567 patients. This prognostic factor analysis was published except that geography was not entered into the analysis. 23 The analysis was repeated on data obtained in all patients, including the subgroups of 2695 patients with complete data and 1378 patients who received only a placebo. Univariate analysis was performed first using the 3-month dichotomous GOS outcome as the dependent variable. The 34 demographic, clinical, radiographic, treatment-related, and in-hospital complication variables described above, as well as geography (country, continent, or region) were the independent variables. Univariate and multivariate unconditional logistic regression analyses were performed as described above.
Multivariate logistic regression with the dependent variable defined as the 5-point GOS score was also conducted. Proportional odds modeling was done first but was abandoned because many variables did not meet the proportional odds assumption. Therefore, polytomous logistic regression was used first to select significant variables based on a maximum likelihood estimation. Next, the significant independent variables were entered into a multivariate polytomous logistic regression. Relative risk ratios and 95% CIs were calculated. Interactions were assessed as well as the effect of tirilazad.
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All data are presented as means ± standard devia- tions, and probability values < 0.05 are considered significant.
Results
Variation in Treatment by Country, Continent, and Region
There was significant variation in treatment between countries, continents, and regions (Table 1 ). Only data tabulated by continent and some of the key variables showing differences are shown for simplicity (complete data available from R. L. Macdonald on request). In the multinomial logistic regression with geography as the dependent variable and the US (for country) or North America (for continent or region) as the reference variable, treatments that varied significantly were antiepileptic drug use, prophylactic hemodilution, hypervolemic therapy, prophylactic hypervolemia, any hemodynamic therapy, and time to surgery ( Table 2 ). The use of prophylactically induced hypertension differed significantly among continents, while the use of hypertensive therapy differed significantly among regions. Similar results were obtained using logistic regression with treatment as the dependent variable. Treatments that consistently varied geographically in all analyses included antiepileptic drug use, prophylactic hemodilution, hypervolemic therapy, any hemodynamic therapy, and time to surgery (data not shown). Several other treatment variables, mainly related to the components of hemodynamic therapy, also varied geographically. The analysis was essentially the same when performed in 2695 patients with complete data available and in the 1378 patients who received a placebo (data not shown).
Variation in Outcome by Country, Continent, and Region
When outcome was assessed as a binary variable in patients with complete data, univariate analysis found multiple significant variables (complete data available from R.L. Macdonald on request; p < 0.05). The key findings were that country and region were significantly associated with outcome in the univariate analysis. Imputation of missing values resulted in loss of significant association between admission temperature and outcome, but no effect on the significance of country or region. Two analyses using the 5-point GOS as the dependent variable were performed inn patients with complete data, which yielded similar results to the binary GOS, except that time from SAH to admission and prophylactic hemodilution became significant (p < 0.05) and admission temperature and diastolic blood pressure were not significant. Country and region remained significant as in the first univariate analysis.
Multivariate analysis of patients with complete data using the dichotomized GOS found that unfavorable outcomes were associated with increasing age, worse admission World Federation of Neurosurgical Societies grade, greater SAH thickness on admission CT scans, posterior circulation ruptured aneurysm location, larger ruptured aneurysm, intraventricular hemorrhage, intracerebral hematoma, higher systolic blood pressure on admission, history of hypertension, prior SAH, MI, and/or liver disease, temperature 38°C or higher on postoperative Day 8, anticonvulsant use, not using prophylactic or therapeutic hypervolemia or prophylactically induced hypertension, symptomatic vasospasm, and cerebral infarction ( Table  3) . Country, continent, or region were not significant variables. The same factors were significant when only data from patients in the placebo group were analyzed. Multivariate analysis was performed with the data obtained in all patients with imputed values. The only difference was that liver disease and diabetes mellitus-of marginal significance in the first analysis-were no longer significant.
The importance of missing values was assessed by generating variables coding admission temperature as present or missing. This had minor effects on some prognostic factors such as liver disease and diabetes mellitus, but no effect on country, continent, and region.
Multivariate logistic regression was also conducted using the 5-point uncollapsed GOS. Ordinal logistic regression using the proportional odds assumption was not appropriate due to variability in ORs between the 5-point GOS levels (χ 2 < 0.001). Multinomial and stereotype logistic regression analyses were therefore performed. The significant factors were identical to those using a binary GOS ( Table 3 ), except that not using prophylactically induced hypertension became insignificant. Again, country, continent, and region were not significantly associated with outcome.
Discussion
In this large data set of patients with aneurysmal SAHs, where the patient was treated geographically did not have any effect on outcome as assessed with the GOS 3 months after SAH. Little has been published on the influence of geography on mortality rate and outcome after SAH. Most research has focused on the epidemiology of SAH, and has attempted to identify and explain regional variations in its incidence.
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In contrast, research has examined regional variations in the incidence and management of stroke in general. The use of preventive measures and control of modifiable risk factors has resulted in a significant decline in cerebrovascular disease in some regions. 24, 31 Specialized stroke units and neurological intensive care units has been suggested to improve outcome in patients suffering from strokes of mild-to-moderate severity and from SAH. 26, 29, 30 Regional variations in stroke treatment do exist and have been attributed to lack of resources, poor public health education, and/or physician experience, knowledge, and preference.
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Even within the US, outcome has been suggested to be better in high-volume centers and when various other treatments are used, such as intensive care management by specialists trained in neurocritical care. 1, 6, 25 On the other hand, these analyses are hampered by inability to stratify patients for prognostic factors for outcome, coding errors and endpoints that may not be the best.
2,9
Why then was geography not significant in this study? One hypothesis is that the centers in the tirilazad studies had similar resources. Resource utilization and outcome in patients treated in Canada and the United States in the tirilazad studies was analyzed.
10 There were differences in resource use such as length of stay but no effect on outcome. The results of this analysis also demonstrated differences in treatments that might be implemented in the intensive care unit and in the use of anticonvulsant agents. 23 Even variation in time to surgery was present, which could affect rebleeding. Time to surgery was associated with outcome in our prior analysis. 23 In the cooperative timing study, there was variation in time of surgery and outcome among centers, but it is not clear that other prognostic factors were corrected for. 16 The timing of surgery, however, varied over hours in the tirilazad studies and over days in the timing study, so the effect of timing would be reduced in the tirilazad studies. Another possibility is that the effect of variations in medical management are small and a larger sample size may be necessary to detect effects of these on outcome.
The limitations of this analysis are that the patients are derived from clinical trials. Patients in clinical trials are subject to greater scrutiny and tend to do better than those not in trials, which may minimize therapeutic differences.
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Conclusions
The value of this analysis is that at least for the countries and centers included in these studies, where a patient undergoes treatment does not matter much. This information is important when, for example, drug studies are conducted in centers around the world and national regulatory agencies may or may not want to accept the data that come from other nations. 
